Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)
{{output}}
Background and objective: This study aimed to develop and validate a prognostic model for overall survival (OS) in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), using clinical factors from phase 3 trials ... ...
